13.12
price down icon7.15%   -1.01
pre-market  プレマーケット:  13.12  
loading
前日終値:
$14.13
開ける:
$14.15
24時間の取引高:
4.45M
Relative Volume:
2.12
時価総額:
$1.34B
収益:
$45.97M
当期純損益:
$-508.80M
株価収益率:
-2.4029
EPS:
-5.46
ネットキャッシュフロー:
$-382.65M
1週間 パフォーマンス:
-18.56%
1か月 パフォーマンス:
-37.76%
6か月 パフォーマンス:
-49.32%
1年 パフォーマンス:
-56.67%
1日の値動き範囲:
Value
$12.82
$14.27
1週間の範囲:
Value
$12.82
$16.28
52週間の値動き範囲:
Value
$12.82
$34.87

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
名前
Intellia Therapeutics Inc
Name
セクター
Healthcare (1193)
Name
電話
857-285-6200
Name
住所
40 ERIE STREET, CAMBRIDGE, MA
Name
職員
598
Name
Twitter
@intelliatweets
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
NTLA's Discussions on Twitter

NTLA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NTLA 13.12 1.34B 45.97M -508.80M -382.65M -5.46
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-02-15 開始されました Wolfe Research Peer Perform
2023-04-13 開始されました Canaccord Genuity Buy
2023-03-21 開始されました Bernstein Outperform
2023-03-14 アップグレード BMO Capital Markets Market Perform → Outperform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2023-01-24 アップグレード Citigroup Sell → Neutral
2023-01-19 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 開始されました Morgan Stanley Overweight
2022-09-21 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Sell
2022-06-17 開始されました BMO Capital Markets Market Perform
2022-06-16 開始されました BofA Securities Buy
2022-04-28 開始されました Credit Suisse Outperform
2022-02-18 開始されました William Blair Outperform
2022-02-07 アップグレード Oppenheimer Perform → Outperform
2022-01-31 開始されました Cowen Outperform
2022-01-07 開始されました Piper Sandler Overweight
2021-10-05 開始されました Guggenheim Buy
2021-09-24 開始されました Stifel Buy
2021-06-28 繰り返されました H.C. Wainwright Buy
2021-06-11 開始されました H.C. Wainwright Buy
2021-05-07 アップグレード ROTH Capital Neutral → Buy
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-03-04 開始されました JMP Securities Mkt Outperform
2020-12-22 ダウングレード Robert W. Baird Outperform → Neutral
2020-10-27 開始されました Truist Buy
2020-10-14 開始されました Wells Fargo Overweight
2020-09-18 開始されました Goldman Buy
2020-02-28 アップグレード Oppenheimer Perform → Outperform
2020-02-14 ダウングレード Wedbush Outperform → Neutral
2019-11-01 アップグレード Raymond James Mkt Perform → Outperform
2019-07-09 開始されました Robert W. Baird Outperform
2019-06-10 開始されました ROTH Capital Neutral
2019-05-03 アップグレード Wedbush Neutral → Outperform
2019-04-12 開始されました Evercore ISI Outperform
2018-11-02 ダウングレード Wedbush Outperform → Neutral
2018-10-29 開始されました Credit Suisse Neutral
2018-09-21 開始されました Raymond James Mkt Perform
2018-05-15 アップグレード Chardan Capital Markets Neutral → Buy
2018-03-08 開始されました JMP Securities Mkt Outperform
2017-11-01 繰り返されました Jefferies Buy
2017-06-22 再開されました Jefferies Buy
2017-03-28 開始されました Chardan Capital Markets Buy
2016-08-05 アップグレード Jefferies Hold → Buy
すべてを表示

Intellia Therapeutics Inc (NTLA) 最新ニュース

pulisher
Nov 20, 2024

Intellia Therapeutics price target lowered to $55 from $76 at Barclays - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

CF Foundation invests $15M in Recode Therapeutics to boost CF gene editing - Cystic Fibrosis News Today

Nov 19, 2024
pulisher
Nov 19, 2024

Intellia Therapeutics Announces Promising CRISPR Therapy Results - Yahoo Finance

Nov 19, 2024
pulisher
Nov 19, 2024

Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo - Yahoo Finance

Nov 19, 2024
pulisher
Nov 18, 2024

Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade) - Seeking Alpha

Nov 18, 2024
pulisher
Nov 18, 2024

Wells Fargo & Company Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $70.00 - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Intellia Therapeutics (NASDAQ:NTLA) Sees Unusually-High Trading Volume Following Analyst Upgrade - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest - BioPharma Dive

Nov 18, 2024
pulisher
Nov 18, 2024

Intellia Therapeutics' (NTLA) Neutral Rating Reaffirmed at Wedbush - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $91.00 at Chardan Capital - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Intellia stock touches 52-week low at $13.94 amid biotech slump - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Intellia’s gene editing therapy shows early potential in rare heart condition - Clinical Trials Arena

Nov 18, 2024
pulisher
Nov 18, 2024

CF Foundation Invests Up to $15 million in ReCode Therapeutics to Develop a Gene Editing Therapy - Yahoo Finance

Nov 18, 2024
pulisher
Nov 18, 2024

The Best Biotech Stocks to Buy - Morningstar

Nov 18, 2024
pulisher
Nov 16, 2024

Intellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year LowHere's Why - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

Intellia Announces First Clinical Evidence from Ongoing - GlobeNewswire

Nov 16, 2024
pulisher
Nov 16, 2024

Intellia's CRISPR Therapy Shows 90%+ Disease Protein Reduction in Key Clinical Trial | NTLA Stock News - StockTitan

Nov 16, 2024
pulisher
Nov 16, 2024

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Gene Editing Tools Market Size, Growth Opportunities, - openPR

Nov 15, 2024
pulisher
Nov 15, 2024

Sumitomo Mitsui Trust Group Inc. Has $64.72 Million Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Intellia Therapeutics (FRA:38I) Operating Income : €-492.77 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

When (NTLA) Moves Investors should Listen - Stock Traders Daily

Nov 14, 2024
pulisher
Nov 12, 2024

Intellia Therapeutics' SWOT analysis: gene editing stock's progress and potential - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace

Nov 12, 2024
pulisher
Nov 11, 2024

3 Fast-Growing Stocks Analysts See Doubling in Price - sharewise

Nov 11, 2024
pulisher
Nov 11, 2024

Oppenheimer Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $60.00 - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Intellia Therapeutics price target lowered to $60 from $70 at Oppenheimer - TipRanks

Nov 11, 2024
pulisher
Nov 11, 2024

Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus (NASDAQ:NTLA) - Seeking Alpha

Nov 11, 2024
pulisher
Nov 11, 2024

Brookline Capital Management Forecasts NTLA FY2027 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 10, 2024

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2024 Earnings Call Transcript - MSN

Nov 10, 2024
pulisher
Nov 09, 2024

Intellia Therapeutics (NASDAQ:NTLA) Upgraded at StockNews.com - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus - MSN

Nov 09, 2024
pulisher
Nov 09, 2024

Intellia Therapeutics (NASDAQ:NTLA) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? - MSN

Nov 08, 2024
pulisher
Nov 08, 2024

Intellia Earnings: Early-Stage Pipeline Makes Progress; Shares Attractive for Long-Term Investors - Morningstar

Nov 08, 2024
pulisher
Nov 08, 2024

Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $55.00 by Analysts at Barclays - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlight - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ... - Yahoo Finance Australia

Nov 08, 2024
pulisher
Nov 08, 2024

ARK Investment Management LLC Buys 659,651 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Intellia Therapeutics Reports Q3 2024 Financial Progress - TipRanks

Nov 07, 2024
pulisher
Nov 07, 2024

Intellia Therapeutics price target lowered to $40 from $41 at JonesResearch - TipRanks

Nov 07, 2024
pulisher
Nov 07, 2024

Intellia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

Intellia Therapeutics Inc earnings beat by $0.05, revenue topped estimates - Investing.com

Nov 07, 2024
pulisher
Nov 07, 2024

Intellia Therapeutics reports Q3 EPS ($1.34), consensus ($1.39) - TipRanks

Nov 07, 2024
pulisher
Nov 07, 2024

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Intellia (NTLA) Advances Phase 3 Trials Despite $135.7M Loss; $944.7M Cash Runway to 2026 | NTLA Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 06, 2024

Harbor Capital Advisors Inc. Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Intellia Therapeutics (NTLA) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Nov 05, 2024

Intellia Therapeutics Inc (NTLA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
大文字化:     |  ボリューム (24 時間):